Abstract
Metformin has been tested for many decades by an oral antidiabetic agent. It is a complex acting drug with significant potential to reduce hyperglycemia and a beneficial cardiovascular effect.
It does not increase the risk of hypoglycaemia, does not increase weight and is caridovascularly protective in monotherapy or in combination with new antidiabetic agents. Randomized clinical trials to test metformin and new head-to-head antidiabetes have not yet been performed.
It can be assumed that the cardiovascular protection of both metformin and new antidiabetes could potentiate. Metformin is the first-line treatment for type 2 diabetics in patients with pre-diabetes.